ABSTRACT A double blind prospective study of the effect of almitrine bismesylate and placebo on peripheral-nerve function was carried out in 12 patients with chronic bronchitis and arterial hypoxaemia (mean (SD) FEV, % predicted 38 (16), arterial oxygen tension (Pao2) 7 56 (076) kPa). Of the seven patients who took placebo, none developed symptoms or signs of peripheral neuropathy. One patient who had abnormal lower limb sensory nerve conduction initially showed improvement of sensory conduction but deterioration in motor conduction during the 12 month study period. Two further patients developed some slowing ofmotor conduction velocities in their right lateral popliteal nerve. Five patients received almitrine and all showed an improvement in Pao2 (mean from 7 0 to 7 9 kPa). None had symptoms or signs of peripheral neuropathy on entry to the study; one patient had evidence of impaired nerve conduction on electrophysiological testing. Three patients developed symptoms and signs of peripheral neuropathy during the 12 months of the study and a fourth developed peripheral neuropathy at 18 months, having continued to receive almitrine. Studies of nerve physiology showed abnormalities in the lower limbs of all four patients. Recovery was poor, possibly because of the long half life of almitrine. The studies suggest that almitrine may precipitate peripheral neuropathy in patients with chronic obstructive pulmonary disease. Patients should be warned of this potential complication so that the drug can be stopped as soon as symptoms develop.
Introduction
Almitrine bismesylate is a respiratory stimulant, which increases arterial oxygen tension in patients who are hypoxaemic from chronic bronchitis.' It appears to act peripherally via the carotid body2 to increase ventilation3 or to redress pulmonary ventilationperfusion imbalance.4 After extensive investigation in Europe there have been sporadic reports of peripheral neuropathy from several countries, including Britain. '7 Symptoms of peripheral neuropathy are said to be relatively common in patients with chronic bronchitis and emphysema, with 40% of 146 unselected patients experiencing sensory symptoms in one study.8 Subclinical peripheral neuropathy, as determined by studies of nerve electrophysiology, is even more common, an incidence of 60-87% being reported.F"
In hypoxaemic patients taking either almitrine or placebo two groups of workers have found no difference in the incidence of peripheral neuropathy, either clinically or on electrophysiological testing, suggesting that hypoxaemia rather than almitrine may be the important factor in peripheral neuropathy. '23 Patients who develop peripheral neuropathy while taking almitrine may have an Peripheral nerve function in patients with chronic bronchitis receiving almitrine or placebo A  54  F  18  27  745  505  737  479  B  62  F  68  09  825  452  86  585  C  59  M  49  21  86  505  81  545  D  63  M  30  2 3  7-78  5-52  745  5 59  E  52  M  22  3 2  745  545  7-58  505  F  58  M  55  1-3  8 1  4 52  6-65  4-66  G  70  M  41  08  798  466  891  505  Mean  59 7  2F SM 41  1 concentration. After 12 months the code was broken and patients who had received almitrine were given the option to continue almitrine if they thought that their symptoms had improved and they agreed to further follow up. All patients were seen three months after cessation of treatment to assess the effect of stopping the trial drug and after another three months if they had developed peripheral neuropathy.
Spirometry was performed with a dry wedge spirometer (Vitalograph), blood gas tensions were determined with a Corning blood gas analyser and carboxyhaemoglobin with a CO-oximeter, biochemical measurements were made on a multichannel analyser, and haematological investigations were done with a Coulter counter. Any patient who developed symptoms or signs of peripheral neuropathy was investigated further-with a full drug and alcohol history, clinical examination, chest radiography, and the following blood tests: autoimmune screen, antinuclear factor, blood glucose and vitamin B12 concentrations, erythrocyte sedimentation rate, and serological tests to exclude syphilis.
Electrophysiological studies of peripheral nerves were undertaken during the three week stabilisation period and after 12 months' treatment (or earlier if peripheral neuropathy developed), a Medelec MS92 machine and standard techniques being used.'4 The studies were performed and interpreted by one person, who was unconnected with the trial. Sensory nerve action potential onset latencies of both ulnar and median nerves were obtained by orthodromic stimulation with ring electrodes and recording with surface electrodes at the wrist. Both sural nerves were stimulated antidromically with recordings made lateral to the Achilles tendon for determination of conduction velocities and amplitudes. Ulnar and median nerves (between the wrist and the elbow) and the lateral popliteal nerves (between the fibular head and lateral malleolus) on both sides were stimulated supramaximally, with surface recordings over the appropriate muscle to obtain maximal motor conduction velocities. Normal values for a population aged over 40 years were based on our own laboratory data and agree with published results.'5 In the lower limb motor conduction velocities below 40 m/s and sensory conduction velocities below 30 m/s were taken as abnormal.
Results for blood gas analyses are expressed as means with standard deviations in parentheses. Paired and unpaired t tests were used to make comparisons within and between groups, p < 0-05 being taken as significant. (table 3a) .
In the patients who received almitrine the initial neurophysiological studies showed abnormality only in patient I (slow sensory conduction velocities in the sural nerves, borderline normal conduction in the lateral popliteal nerves). Patient 2 had borderline normal conduction velocities in the right sural nerve prior to treatment.
At the end of the study patient I had abnormal motor conduction velocity in the left leg and loss ofthe right sural action potential (table 3b) . Patient 2, studied after nine months' treatment, showed reduced motor conduction velocities in both legs, although sural nerve conduction velocity was improved. In patient 3 no action potential could be detected from the left sural nerve and there was some reduction in both lower limb motor conduction velocities. Patient 4 had no changes in the 12 month study, but at 18 months lower limb muscle denervation was present on the concentric needle electromyogram in keeping with axonal neuropathy. For patient 5 the only abnormality was the absence of any sensory action potential from the right sural nerve.
ARTERIAL BLOOD GAS CHANGES
In the placebo treated group there were no significant changes in arterial blood gases during the study. In the almitrine treated group all five patients showed an increase in Pao2 (p < 0-01) with a mean rise of 0-88 (026) kPa. Mean Paco2 and hydrogen ion concentrations were unchanged (table 1).
Discussion
The main finding of this prospective study is the high tDenervation evident from muscle sample at 18 months. 295 296 incidence of both clinical and electrophysiological abnormalities in the peripheral nerves of patients receiving almitrine. Only two of the 12 patients had electrophysiological evidence of neuropathy on entry into the study, a considerably lower proportion than the 60-87% reported in some French and North American studies of hypoxaemic patients with chronic bronchitis." 16 17 No patient who received placebo showed clinical evidence of peripheral neuropathy, though patient A developed the carpal tunnel syndrome. Electrophysiological studies of nerve function before treatment in this group showed a sensory nerve abnormality in one patient only (patient A), though two other patients had borderline normal lower limb motor conduction. Over the 12 months two patients showed a reduction in motor conduction velocities below the normal values in the right lateral popliteal nerves. No lower limb sensory nerve abnormalities developed during the study (patient A showed an improvement in sural nerve function). Upper limb nerve studies gave normal results before and after the 12 month period in all patients except the one who developed the carpal tunnel syndrome.
None of the patients in the almitrine group had clinical evidence of peripheral neuropathy at the start of the study; three developed symptoms and signs of peripheral neuropathy during the study and a fourth after 18 months' almitrine treatment. In one patient this was of sufficient severity to warrant withdrawal from the study at nine months.
In the five patients receiving almitrine the results of nerve conduction studies were abnormal in only one patient and borderline in a second at the start of the study. After almitrine treatment neurophysiological studies gave abnormal results in all five patients, although not until 18 months in patient 4. In patient 5, who did not have clinical neuropathy, only the right sural nerve action potential was lost and the significance of this is not clear.
Why patients with chronic bronchitis develop peripheral neuropathy is unknown. A relationship may exist between the duration of the hypoxaemia, its severity, and symptoms of neuropathy,"18 although this has been questioned.89 Hypoxaemia producing impairment of axonal transport mechanisms in long nerve fibres has been suggested,'920 and this may explain why only lower limb abnormalities were detected before and after the study (if we exclude the patient with the carpal tunnel syndrome).
Poor nutrition leading to vitamin deficiencies has been suggested as a factor, although the evidence for this is poor.9 Hydrocyanic acid and carbon monoxide from tobacco smoke may be important."' 16 Our patients did not claim to have reduced their tobacco consumption before entering the study, so smoking Allen, Prowse seems unlikely, given their carboxyhaemoglobin concentrations, to have been the cause of their neuropathy.2' People who smoke are more likely to have a high intake of alcohol, a well recognised neurotoxin.22 National variations in the amount of alcohol ingested may explain differences in the reported incidence of peripheral neuropathy between countries. All of our patients, however, denied alcohol abuse, and had normal y glutamyl transferase activity and mean corpuscular volumes, making alcohol an unlikely cause of the peripheral neuropathy. Drugs used in the management of patients with chronic bronchitis are rarely associated with the development of neuropathy2324 and a detailed drug history was unhelpful. The additional investigations we carried out failed to identify any cause for the neuropathy.
Only one other study has addressed the importance of underlying neuropathy in patients with chronic bronchitis taking almitrine. Lerebours et alenrolled 22 patients with chronic bronchitis and emphysema in an open study of almitrine 50 mg twice daily. At the time of publication 13 had completed one year's treatment; none had developed either clinical or electrophysiological neuropathy." Unfortunately changes in arterial blood gas tensions and blood almitrine concentrations were not given and lower limb sensory potentials, which are probably more sensitive in detecting early changes, were not measured.
From the small number of patients we studied we cannot say for certain that the peripheral neuropathy was caused directly by almitrine, but almitrine seems likely to have acted as the precipitating agent in patients predisposed to the condition, perhaps by hypoxaemia. Peripheral neuropathy, however, has been reported in six patients who were taking almitrine combined with raubasin for "chronic cerebrovascular insufficiency" and who had no evidence of chronic respiratory disease and presumably were not hypoxaemic.26 Interestingly, the four patients who developed peripheral neuropathy had relatively high mean blood almitrine concentrations and the neuropathy developed earliest in the man with the highest concentration. This suggests that the blood concentration of almitrine achieved with treatment, especially if it continues to rise, may be relevant to the development of neuropathy.
Our initial clinical examination did not identify which patients might be at risk of developing neuropathy and neurophysiological studies identified a pre-existing abnormality in only one of the four patients receiving almitrine who developed peripheral neuropathy. Detailed nerve conduction studies are time consuming for both patient and operator and are not available in many hospitals. There seems to be no strong indication for undertaking these as a routine before starting treatment with almitrine.
